ICC hears fight over drug for Kennedy’s disease
Shutterstock, Bits And Splits
A US pharmaceutical company has asked an ICC emergency arbitrator to halt its Taiwanese partner’s development of a drug to treat a rare neuromuscular disease – a dispute arising from a US$250 million licensing deal.
To read more
Subscribe to Global Arbitration Review
Register for limited access
Register for free to receive GAR’s daily briefing and access to GAR 100.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.
Subscribe now